<DOC>
	<DOCNO>NCT00531115</DOCNO>
	<brief_summary>The purpose study determine confirm objective response rate combination therapy cetuximab plus XELOX 4 cycle follow maintenance treatment cetuximab plus capecitabine first line treatment elderly patient metastatic colorectal cancer</brief_summary>
	<brief_title>Phase II Study Evaluate Safety Efficacy Cetuximab Combination With XELOX 12 Weeks Followed Maintenance Treatment With Cetuximab Plus Capecitabine First-line Treatment Elderly Patients With Metastatic Colorectal Cancer .</brief_title>
	<detailed_description>- This open-label , non-controlled , multicentre , phase II study recruit 53 elderly patient diagnosis metastatic colorectal cancer . - All patient receive 4 cycle treatment cetuximab plus XELOX follow cetuximab plus capecitabine maintenance therapy progression disease , occurrence unacceptable toxicity study drug , withdrawal consent patient . - The planned duration cycle 3 week . - Cetuximab therapy delay chemotherapy-related toxicity vice versa . If patient benefit combination therapy , develop unacceptable intolerance oxaliplatin and/or capecitabine , cetuximab may continue combination chemotherapy drug and/or single agent . In case cetuximab intolerance , patient continue chemotherapy treatment progression disease . - Evaluations : - Efficacy data ( response rate , progression-free survival , duration response survival ) safety data collect . The investigator assess response treatment . - When treatment stop either disease progression occurrence unacceptable toxicity , patient enter follow-up period progression-free survival , subsequent line treatment survival data collect every 12 week .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed write informed consent study related activity carry Men woman &gt; = 70 year . Histologically confirm diagnosis CRC . Nonresectable and/or nonoperable metastatic colorectal carcinoma . Presence least one lesion twodimensional measurement ; index lesion region previous irradiation . Availability tumor tissue immunohistochemical analysis Karnofsky functional status &gt; = 80 % time enrollment study . Life expectancy great 3 month . Patients receive chemotherapy advance metastatic disease . Patients follow characteristic include : 1 . Recurrence neoadjuvant and/or adjuvant treatment 5fluorouracil/folinic acid capecitabine +/ radiotherapy diseasefree interval &gt; 12 month follow conclusion treatment . 2 . Recurrence surgical and/or radiotherapy treatment without adjuvant systemic treatment . 3 . De novo diagnosis disease . Proper hematological , renal hepatic function , Documented suspect cerebral and/or leptomeningeal metastasis . Surgery ( exclude biopsy diagnosis ) and/or radiotherapy 4 week prior inclusion study . Chronic , concomitant systemic immunotherapy , chemotherapy , hormonal treatment cancer . Prior administration monoclonal antibody , EGFR signal transduction inhibitor EGFRtargeted treatment . Participation another clinical trial medication past 30 day Prior participation study treatment cetuximab may assign ( whether treatment cetuximab receive ) . Prior malignant tumor past 5 year , except history adequately treat basal cell skin cancer preinvasive cervical cancer . Lack physical integrity upper gastrointestinal tract malabsorption syndrome history inflammatory intestinal disease , acute subacute intestinal occlusion disease could alter drug absorption . Evidence grade 3 4 allergic reaction treatment component fluoropyrimidines . Clinically relevant peripheral neuropathy . Clinically significant coronary artery disease history myocardial infarction last 12 month high risk decompensation heart failure arrhythmia . Serious active infection ( require intravenous antibiotic ) , include active tuberculosis diagnose HIV . Known abuse alcohol/drugs . Legal incapacity limit legal capacity . Any medical psychological disorder , opinion investigator , allow patient conclude study sign inform consent . Patients catalogue delicate `` frail '' compliance follow criterion Dependence one activity daily life accord Katz Activity Daily Living ( ADL ) scale . 3 comorbid entity base evaluation presence follow process : congestive heart failure ; valvular heart disease ; coronary artery disease ; obstructive restrictive chronic pulmonary disease ; cerebrovascular disease ; peripheral neuropathy ; chronic renal failure ; hypertension ; diabetes ; concomitant neoplasm ; collagen vascular disease ; incapacitate arthritis . Presence geriatric syndrome : moderatesevere dementia ; delirium situation stress ( urinary respiratory infection , angina drug ) ; moderatesevere depression interferes usual activity patient ; frequent fall ( 3 per month ) ; lack care ( Who could help event emergency ? ) ; urinary incontinence absence stress , infection , diuretic prostatic hyperplasia ; fecal incontinence absence diarrhea laxatives ; osteoporotic fracture long bone vertebral crush .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>elderly patient</keyword>
	<keyword>cetuximab , oxaliplatin , capecitabine</keyword>
</DOC>